- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.09. | METIS TECHBIO-P (07666): 2026 INTERIM REPORT | 3 | HKEx | ||
| 04.09. | METiS TechBio revenue surges on licensing deal | 1 | China Daily | ||
| 25.08. | METIS TECHBIO-P (07666): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 12.08. | METIS TECHBIO-P (07666): DATE OF BOARD MEETING | 1 | HKEx | ||
| 04.08. | METIS TECHBIO-P (07666): (1) APPOINTMENT OF JOINT COMPANY SECRETARY; AND (2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES | - | HKEx | ||
| 03.08. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ANNOUNCES COLLABORATION WITH HENGRUI PHARMACEUTICALS ON THE AITEM ARTIFICIAL INTELLIGENCE ... | 2 | HKEx | ||
| METIS TECHBIO Aktie jetzt für 0€ handeln | |||||
| 31.07. | METIS TECHBIO-P (07666): (1) RESIGNATION OF CHIEF FINANCIAL OFFICER, BOARD SECRETARY AND JOINT COMPANY SECRETARY AND CHANGE OF PROCESS AGENT; (2) CHANGE ... | 2 | HKEx | ||
| 30.06. | Deerfield's Boulevard Bio pens $1.6B deal for trispecific TCE from China's Metis TechBio | 2 | FierceBiotech | ||
| 30.06. | Metis TechBio seals $1.62b global licensing deal with Boulevard Bio | 1 | China Daily | ||
| 30.06. | METiS TechBio vergibt Lizenz für Wirkstoffkandidaten in 1,6-Milliarden-Dollar-Deal | - | Investing.com Deutsch | ||
| 30.06. | METiS TechBio licenses drug candidate to Boulevard Bio for $1.6B | 3 | Investing.com | ||
| 30.06. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ANNOUNCES A PRECLINICAL TCE LICENSING COLLABORATION WITH DEERFIELD OF UP TO US$1.6 BILLION | 2 | HKEx | ||
| 22.06. | METIS TECHBIO-P (07666): NOTIFICATION LETTER TO NON-REGISTERED HOLDERS OF AND REQUEST FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 22.06. | METIS TECHBIO-P (07666): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 12.06. | METIS TECHBIO-P (07666): CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF ... | 1 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 05.06. | METIS TECHBIO-P (07666): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | 3 | HKEx | ||
| 26.05. | METIS TECHBIO-P (07666): CLARIFICATION ANNOUNCEMENT | 2 | HKEx |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 63,60 | +0,39 % | Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom? | ||
| MANNKIND | 2,925 | -0,58 % | MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow' for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) | ||
| NEOVACS | 0,107 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 259,86 | 0,00 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,590 | 0,00 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| QIAGEN | 40,190 | +1,55 % | Pharma-Aktien starten durch: Merck, Qiagen und Bayer im Höhenflug - KI-Boom und US-Megadeal befeuern Branche | Die Aktien von Pharma- und Biotech-Unternehmen erleben am Dienstag einen starken Aufwärtstrend, angeführt von Merck KGaA. Investoren setzen auf Übernahmespekulationen und den KI-getriebenen Innovationsschub... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 79,78 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| MODERNA | 200,50 | -0,17 % | Moderna-Aktie: Steht der Ausbruch bevor? | Die Moderna-Aktie setzt ihre spektakuläre Erholung fort und notiert bei 190,01 US$. Damit hat der Kurs der Moderna-Aktie eine mehrjährige Widerstandszone überwunden. Der Ausbruch eröffnet technisch... ► Artikel lesen | |
| NURIX THERAPEUTICS | 22,350 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,360 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 112,45 | 0,00 % | Kymera Therapeutics: Raymond James startet Coverage mit "Outperform"-Rating | ||
| TANGO THERAPEUTICS | 23,820 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| IMMUNOVANT | 30,470 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen |
Das Unternehmen METIS TECHBIO CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,119 (-6,74 %) liegt der Kurs bei 1,647 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu METIS TECHBIO CO LTD finden Sie auf Wallstreet Online.